Sharenet Sites 
Sharenet Sites
Trading statement for the year ended 30 June 2022
Ascendis Health Limited
(Registration number 2008/005856/06)
(Incorporated in the Republic of South Africa)
Share code: ASC
ISIN: ZAE000185005
(“Ascendis Health” or “the Group”)
TRADING STATEMENT FOR THE YEAR ENDED 30 JUNE 2022
In terms of paragraph 3.4(b) of the JSE Limited Listings Requirements, companies are required to publish a
trading statement as soon as they are satisfied, with a reasonable degree of certainty, that the financial
results for the period to be reported upon next will differ by at least 20% from those of the previous
corresponding reporting period.
Accordingly, the board of directors of Ascendis advises shareholders that it is reasonably certain that the
financial results for the year ended 30 June 2022 (the “current period”), when compared with the published
results for the year ended 30 June 2021 (the “prior corresponding period”), are expected to differ as follows:
Continuing operations1:
• Basic loss per share (“LPS”) from continuing operations of between 141.6 cents and 173.1 cents per
share compared to the restated LPS from continuing operations of 351.1 cents for the prior corresponding
period, representing an improvement of between 209.5 cents and 178.0 cents (59.7% and 50.7%).
• Headline loss per share (“HLPS”) from continuing operations of between 109.6 cents and 134.0 cents
compared to a restated HLPS from continuing operations of 334.7 cents for the prior corresponding
period, representing an improvement of between 225.1 cents and 200.7 cents (67.3% and 60.0%).
• Normalised headline loss per share (“NHLPS”)2 from continuing operations of between 98.5 cents and
120.4 cents compared to a restated NHLPS from continuing operations of 282.4 cents for the prior
corresponding period, representing an improvement of between 183.9 cents and 162.0 cents (65.1% and
57.4%).
Total operations:
• Basic earnings per share (“EPS”) from total operations of between 83.8 cents and 102.4 cents per
share compared to the LPS from total operations of 226.5 cents for the prior corresponding period,
representing an improvement of between 310.3 cents and 328.9 cents.
• HLPS from total operations of between 72.4 cents and 88.4 cents compared to a HLPS from total
operations of 115.6 cents for the prior corresponding period, representing an improvement of between
43.2 cents and 27.2 cents (37.4% and 23.5%).
• NHLPS from total operations of between 13.8 cents and 16.9 cents compared to a NHLPS from total
operations of 25.9 cents for the prior corresponding period, representing an improvement of between 12.1
cents and 9.0 cents (46.7% and 34.8%).
1 The comparatives have been restated for the change in discontinued operations.
2 Normalised EBITDA, Normalised headline earnings and normalised headline earnings per share are alternative
performance measures or non-IFRS measures. Further details regarding the computation of the performance measures
and its purpose can be found on the Company’s website via
https://ascendishealth.com/wp-content/uploads/2020/09/Ascendis-Health-Performance-Measures-30-June-2020.pdf
Restatement of comparative results
The current period results reflect the results of Pharma under discontinuing operations in line with the
requirements of IFRS 5: Non-current assets held for sale and discontinued operations, and those of Medical
Devices and Consumer Health as continuing operations. The comparative results disclosed for the prior
corresponding period have been restated accordingly.
The reconciliation below provides a high-level overview of the impact of the reclassification of discontinued
operations:
Continuing operations
Loss from Loss from
continuing continuing Loss Headline Normalised
Normalised operations operations per loss per headline loss
Revenue EBITDAPM before tax after tax share share per share
R'm R'm R'000 R'000 cents cents cents
As reported FY2021 2 229 14 (1 546) (1 616) (343.1) (325.9) (273.1)
Transfer to discontinuing operations (404) (39) 15 (39) (8.0) (8.8) (9.3)
Restated FY2021 1 825 (24) (1 531) (1 655) (351.1) (334.7) (282.4)
This trading statement and operational update is the responsibility of the directors and the financial
information on which this statement is based has not been reviewed or reported on by the external auditors.
Shareholders are advised that company’s annual results will be released on Wednesday, 28 September
2022, with a live webcast of the results presented by Carl Neethling (chief transition officer and acting chief
executive officer) and Cheryl-Jane Kujenga (chief financial officer) at 11:00 on Wednesday, 28 September
2022. Any shareholder who would like to attend the live webcast of the results presentation should contact
the company at investor.relations@ascendishealth.com.
26 September 2022
Bryanston
Sponsor
Questco Corporate Advisory Proprietary Limited
2
Date: 26-09-2022 01:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
